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Background/aim: In recent years ischemia-modified albumin (IMA) has been suggested as a marker that can be used in differentiating
nonconvulsive conditions from epilepsy. The purpose of this study was to investigate changes in IMA levels caused by generalized clonic
tonic (GTC) seizures.
Materials and methods: A total of 114 children presenting to the Karadeniz Technical Pediatric Emergency Polyclinic with GTC
seizures were included in the study. Sixteen cases meeting the inclusion criteria were included in the study and sixteen healthy children
were enrolled as the control group. The patients’ IMA, albumin, and IMA/albumin values at hours 0 and 1 following the episode were
compared with control group values.
Results: IMA levels in the patient group were significantly higher at hour 1 compared to hour 0, and were also significantly higher than
those of the control group levels at hour 1. In addition, the patient group IMA/albumin index value at hour 1 was significantly higher
than the baseline value. IMA levels increased significantly with length of seizure.
Conclusion: Although there were no markers of hypoxia in patients undergoing GTC seizures in this study, hypoxia was observed to
develop, and this caused serum IMA levels to rise in line with seizure duration.
Key words: Ischemia-modified albumin, generalized clonic tonic, albumin, IMA/albumin

1. Introduction
The metal-binding capacity of albumin for transition
metals, such as copper, nickel, and cobalt, is reduced during
acute ischemic conditions. This results in a metabolic
variant of the protein ischemia-modified albumin (IMA)
(1). The observation that myocardial ischemia produced
a lower metal-binding capacity for cobalt to albumin led
to the development of the albumin-cobalt binding (ACB)
test, which was recently approved by the FDA. The ACB
test is a quantitative assay that measures IMA in human
serum (2). Experimental and clinical studies have shown
an increase in IMA levels in blood in various organ
ischemias or injuries, particularly myocardial ischemia,
and systemic ischemias (2–9). One study of patients
with PCI reported that IMA is not only a marker of the
occurrence of an ischemic event, but also an indicator of
the severity of ischemia (10).
* Correspondence: tkamasak@hotmail.com
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Seizures, particularly generalized tonic clonic
(GTC) seizures, give rise to a number of physiological
consequences. Prolonged seizures result in deterioration
of homeostatic mechanisms (11). Ictal hypoxemia has
been studied extensively in children and adults (12,13). In
a study of 225 seizures and 49 epileptic children, Moseley
et al. (13) reported ictal hypoxemia in 48.9% of children
and in 26.8% of seizures. In that study, ictal hypoxemia was
also significantly more likely to occur during generalized
rather than nongeneralized seizures (43.9% vs. 18.9%) and
when tapering antiepileptic drugs (75% vs. 35.5%) (13).
Secondary physiological changes (including hypotension,
hypoxia, hypoglycemia, and hyperthermia) occurring
as the length of epileptic seizures increases contribute to
injury in both the brain and other organs (14).
Ictal hypoxemia during seizure is a well-known
condition. The ability to use biochemical markers to
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determine this condition may be beneficial. The purpose
of this study was to determine whether IMA, regarded
as a good biochemical marker of cerebral or systemic
ischemia/hypoxemia, alters in cases with no markers of
hypoxia following seizures (no acidosis, oxygen saturation
>90%), and to test the association with length of seizure.
For that purpose we compared serum blood IMA levels of
patients undergoing GTC seizures at hours 0 and 1 with
IMA levels in an age- and sex-matched control group at
hours 0 and 1.
2. Materials and methods
This study was conducted at the Karadeniz Technical
University Hospital Department of Pediatric Neurology,
Turkey, with the approval of the institutional ethics
committees and in conformity with the Helsinki
Declaration, ICH/GCP, and local regulations.
A total of 114 children presenting to the Karadeniz
Technical Pediatric Emergency Polyclinic with GTC
seizures and undergoing GTC seizures while under
observation at the EEG monitoring unit were considered
for the study. Patients with seizure duration of 1–5 min,
with postseizure oxygen saturation of >90% and no acidosis
(pH of >7.35), with no chronic or degenerative disease
(diseases of the cardiovascular or respiratory systems,
diabetes, etc.), with negative acute phase proteins and
fever, and with no other epileptic episode in the previous
24 h were selected. Sixteen patients meeting the inclusion
criteria (9 males, 7 females) were included in the study.
Blood specimens were collected at hours 0 and 1. Sixteen
(9 males, 7 females) age- and sex-matched children with
no disease being monitored at the healthy child clinic were
enrolled as the control group.
Patients’ IMA, albumin, and IMA/albumin values at
hours 0 and 1 were compared with control group values.
2.1. IMA measurement
Blood samples were placed into plain tubes containing
separation gels. The samples were allowed to clot for 30
min and were then centrifuged before separating the
serum. The samples were then immediately frozen and
stored at –80 °C for IMA assays.
Reduced cobalt-to-albumin binding capacity (IMA
level) was analyzed using the rapid colorimetric method
described by Bar-Or et al. (15). Two hundred microliters
of patient serum was placed into glass tubes, and 50 µL
of 0.1% cobalt chloride (Sigma, CoCl2.6H2O) in H2O was
added. After gentle shaking, the solution was left for 10
min in order to ensure sufficient cobalt-albumin binding.
Fifty microliters of dithiothreitol (DTT) (Sigma, 1.5 mg/
mL H2O) was added as a colorizing agent. The reaction was
quenched 2 min later with the addition of 1.0 mL of 0.9%
NaCl. A colorimetric control was prepared for preoperative
and postoperative serum samples. For the colorimetric

control samples, 50 µL of distilled water was substituted
for 50 µL of 1.5 mg/mL DTT. Specimen absorbencies were
analyzed at 470 nm on a spectrophotometer (Shimadzu
UV1601, Australia). The color of the DTT-containing
specimens was compared with that of the colorimetric
control tubes. The results were reported as absorbance
units (ABSU).
2.2. Statistical analysis
Data analysis was performed using SPSS 11.5. Descriptive
statistics are shown as mean ± SD. Normality of
distribution (normality test - Kolmogorov–Smirnov test)
was tested in the measured values. Since the data complied
with normal distribution, parametric tests were used in
analyses. Treatment and control groups were compared in
terms of IMA, albumin, and IMA/albumin. Student’s t-test
was used to compare IMA, albumin, and IMA/albumin
(at hour 0 for the control group and at hour 0 postseizure
in the patient group; and at hour 1 in the control group
and hour 1 postseizure in the patient group). The paired
t-test and Student’s t-test were used to compare two values
within the patient group and with the controls (hour 0
and hour 1 values), respectively. The significance of linear
correlation between changes in IMA and length of seizure
(in seconds) was examined using Spearman’s correlation
test. Significance was set at P < 0.05.
3. Results
The mean age of the 16 patients in the patient group was
9.87 ± 2.33 years, and mean age was 9.69 ± 2.33 years in
the 16 control group subjects. Both groups consisted of 9
boys and 7 girls. The groups’ IMA and albumin levels and
IMA/albumin index values are shown in the Table.
Control group IMA levels at hour 1 were lower than at
hour 0 (P < 0.05). No change was observed in control group
albumin levels between hours 0 and 1, and no difference
was observed between IMA/albumin index values.
In the patient group, IMA levels at hour 1 increased
significantly compared to those at hour 0, and they were
also significantly higher than the control group values
at hour 1 (P < 0.05 and P < 0.001, respectively). Patient
group albumin levels at hours 0 and 1 were significantly
lower than the corresponding levels in the control group.
Albumin levels at hour 1 in the patient group were
significantly lower than the values at hour 0 (P < 0.05).
IMA/albumin index values in the patient group at hours
0 and 1 were significantly higher than the corresponding
values in the control group (P < 0.05 and P < 0.001,
respectively). In addition, IMA/albumin index values in
the patient group at hour 1 were significantly higher than
the baseline value (P < 0.01).
A comparison of IMA levels at hours 0 and 1 in the
control and patient groups is shown in Figure 1. Patients’
lengths of seizures were recorded (in seconds). A
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Table. IMA, albumin, and IMA/albumin values in the patient and control groups.
Controls
(n = 16)

Patients
(n = 16)

Hour 0

Hour 1

Hour 0

Hour 1

IMA

0.552 ± 0.030

0.533 ± 0.043

0.586 ± 0.082

0.652 ± 0.082

Albumin

4.56 ± 0.22

4.54 ± 0.21

4.19 ± 0.21

4.04 ± 0.25

IMA/albumin

0.121 ± 0.011

0.118 ± 0.013

0.140 ± 0.026

0.158 ± 0.023

IMA: Ischemia modified albumin.
Values are expressed as mean ± SD; the paired samples t-test was used for intragroup analysis and Student’s t-test
for intergroup analysis.
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Figure 1. Ischemia-modified albumin level changes in generalized tonic clonic seizures.

significant correlation was determined between duration
of seizure and IMA values, with IMA values increasing
with length of seizure (Figure 2).
4. Discussion
IMA increases in myocardial ischemia, cancers, infections,
end-stage renal disease, liver disease, and cerebral
ischemia (2–10,16). This study shows that serum IMA
levels increase even in the absence of hypoxia markers in
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patients undergoing GTC seizures and that serum IMA
values are directly proportional to length of seizure.
The number of studies investigating IMA levels in
conditions involving the central nervous system is limited,
and the findings are inconsistent. Turedi et al. (17) noted
the presence of elevated IMA levels in carbon monoxidepoisoned patients and suggested that IMA is sensitive to
hypoxia. Abboud et al. (18) examined 118 patients (84
brain infarctions, 18 brain hemorrhages, and 16 transient
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Figure 2. Correlation between IMA levels and length of seizure
(in seconds). A significant positive correlation was determined
between length of seizure and IMA levels (r = 0.79; P < 0.001).

ischemic attacks lasting less than 1 h or epileptic seizures)
presenting within 3 h of acute neurological deficit in order
to investigate whether or not stroke affects blood IMA
levels. That study measured IMA in blood specimens
collected from all patients at baseline and from patients
with stroke collected at hours 6, 12, and 24. They reported
that IMA levels rose in the first 24 h in patients with
cerebral infarction but remained unchanged in patients
with cerebral hemorrhages, and they concluded that IMA
levels might be a biomarker for the early diagnosis of acute
stroke. Ahn et al. (19) compared the albumin-adjusted
IMA index and IMA values in patients with ischemic
stroke. They showed that this IMA index was a more
sensitive diagnostic biomarker for stroke than conventional
IMA values but that its value in predicting progression
was questionable. Haklıgör et al. (20) suggested that the
ACB assay reflects albumin concentrations rather than
IMA levels, and that albumin concentration is a primary
predictor of IMA in serum. They observed a strong
negative relationship between albumin concentrations
and IMA, and they reported that IMA values were directly
determined by albumin concentrations at all albumin
levels. Since measurement of IMA values using the ACB
technique relies on measurement of cobalt that does not
bind to albumin, IMA level results will be affected by
albumin concentrations in serum. It is well known that ACB
test results should be interpreted with caution when serum
albumin concentrations are <20 g/L or >55 g/L, or in the
presence of increased lactate or ammonia concentrations
(2). The IMA index may provide more accurate results by
compensating for this effect. The albumin levels in our
study were at appropriate intervals for interpretation. All
patients’ blood gas values were normal. IMA index values
were also used in comparison of the patient and control
groups in order to neutralize the effect of albumin values.
Our study shows that IMA levels and IMA index levels

rose in the 1st hour in patients undergoing GTC seizures
and were significantly higher than control group values.
It also shows a significant positive correlation between
length of GTC seizure and IMA levels.
There are also study findings suggesting limited clinical
potential of IMA as an ischemic marker. Kim et al. (21)
concluded that in clinical practice the use of serum IMA
level does not seem beneficial, neither for the triage of
patients with acute chest pain nor for risk stratification
of patients with ischemic chest pain. Herisson et al. (22)
concluded that IMA does not appear to be relevant in acute
stroke management. It has also been reported although
IMA is not highly specific as a marker of ischemia, it is
quite sensitive when negative (23).
The main limitations of this study are the low case
numbers enrolled and the difficulty in interpreting the
findings. In conclusion, this study shows that certain
levels of hypoxia develop in patients undergoing GTC
seizures even in the absence of hypoxia markers (such as
acidosis and low oxygen saturation), and that this gives
rise to an increase in IMA levels proportional to length of
seizure. Investigation of postseizure serum IMA levels can
therefore provide information concerning hypoxia during
seizure or length of seizure.
In addition, our findings may also show that serum IMA
levels can particularly be used as a biochemical marker in
differentiating nonepileptic and epileptic seizures. The
fact that history of seizure in patients presenting to the
emergency department is generally obtained from families
sometimes makes it difficult to differentiate between
seizure and pseudoseizure. Families are unable to provide
sufficient anamnesis in such circumstances due to the fear
and panic caused by the event. Even if we make use of EEG
in such conditions, we know that interictal EEG recordings
may be normal in many patients. We therefore think that
other markers are needed to differentiate between seizure
and pseudoseizure.
Patients’ lengths of seizures were recorded (in seconds).
A significant correlation was determined between duration
of seizure and IMA values, with IMA values increasing
with length of seizure (Figure 2). In this study, in addition
to an increase in IMA values in generalized seizures, we
also determined a linear correlation between length of
seizure and that IMA values increased with duration
of seizure. We think that in addition to contributing to
differentiating pseudoseizures from seizures, this will also
provide information concerning the duration of seizure in
patients brought to our hospital due to seizures. Due to
the low number of patients meeting the study criteria, we
were unable to compare IMA levels in longer and shorter
seizures with different groups and durations of seizure.
Further studies involving larger patient numbers will
make such comparison possible.
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